Novel ATR Inhibitor Shows Promise in Children With Tumors Novel ATR Inhibitor Shows Promise in Children With Tumors

The novel ataxia telangiectasia –mutated Rad3-related (ATR) inhibitor, ceralasertib, showed some promise in combination with olaparib in pediatric patients with tumors with DNA repair deficiencies.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news